Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
128 hedge funds and large institutions have $766M invested in Acceleron Pharma in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 28 reducing their positions, and 14 closing their positions.
132% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 28
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 125 → 128 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
37% less capital invested
Capital invested by funds: $1.21B → $766M (-$447M)
69% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $6.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$22.6M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$19.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.6M |
| 4 |
PA
Perceptive Advisors
New York
|
+$15.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$19.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.2M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$4.73M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$4.07M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.93M |
XLRN Hedge Fund Activity: Q1 2016 in Review
128 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2016, worth a combined $766M — down 37% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XLRN positions and 14 closed out — a net gain of 3 holders — while 65 added to existing stakes and 28 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $22.6M. The largest seller was Millennium Management, cutting an estimated $19.7M.
- 128 institutional investors held Acceleron Pharma (XLRN) as of Q1 2016, up from 125 in Q4 2015.
- Funds reported $766M of Acceleron Pharma stock for Q1 2016, down 37% quarter-over-quarter.
- 17 funds opened new Acceleron Pharma positions in Q1 2016 and 14 closed out, a net change of +3 holders.
- The largest Acceleron Pharma buyer in Q1 2016 was Eagle Asset Management, an estimated $22.6M added.
- The largest Acceleron Pharma seller in Q1 2016 was Millennium Management, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2016.